Cargando…
The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN)
BACKGROUND: We aimed to explore whether erenumab, a monoclonal antibody targeting the calcitonin gene-related peptide receptor, could exert a central effect on brain network function in migraine, and investigate the persistence of such an effect following treatment discontinuation. METHODS: This was...
Autores principales: | Filippi, Massimo, Messina, Roberta, Bartezaghi, Marta, Cetta, Ilaria, Colombo, Bruno, Grazzi, Licia, Martinelli, Daniele, Ornello, Raffaele, Pichiecchio, Anna, Raimondi, Debora, Russo, Antonio, Sacco, Simona, Splendiani, Alessandra, Tassorelli, Cristina, Turrini, Renato, Valsasina, Paola, Rocca, Maria Assunta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576673/ https://www.ncbi.nlm.nih.gov/pubmed/37550498 http://dx.doi.org/10.1007/s00415-023-11879-9 |
Ejemplares similares
-
Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
por: De Matteis, Eleonora, et al.
Publicado: (2022) -
Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
por: Ornello, Raffaele, et al.
Publicado: (2021) -
The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
por: Ornello, Raffaele, et al.
Publicado: (2019) -
Applying a biopsychosocial model to migraine: rationale and clinical implications
por: Rosignoli, Chiara, et al.
Publicado: (2022) -
Correction: Applying a biopsychosocial model to migraine: rationale and clinical implications
por: Rosignoli, Chiara, et al.
Publicado: (2022)